Search

Type

Audience

Category

Issue

Last updated

Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.

Displaying 1 - 15 of 38 items.

Health alert or recall Distribution of a New Presentation of SPIKEVAX (elasomeran) COVID-19 Vaccine (0.10 mg/mL in 2.5 mL multidose vial) with English-only Vial and Carton Labels
A new presentation of SPIKEVAX (elasomeran) with a concentration of 0.10 mg/mL in a 2.5 mL multidose vial was authorized on June 01, 2022. In order to provide rapid access to the new presentation of SPIKEVAX (0.10 mg/mL, 2.5 mL multidose vial), Moderna…
AlertHealth professional risk communication | 2022-06-06
Health alert or recall Sotrovimab for Injection - Risk of Treatment Failure due to Circulation of SARS-CoV-2 Omicron BA.2 Subvariant
Sotrovimab, 500 mg IV, is unlikely to maintain efficacy against the Omicron BA.2 subvariant. Sotrovimab demonstrates reduced in vitro neutralization against the Omicron BA.2 subvariant.   Audience  Healthcare professionals responsible…
AlertHealth professional risk communication | 2022-04-14
Health alert or recall Distribution of EVUSHELD (tixagevimab and cilgavimab for injection) with English-Only Vial and Carton Labels
EVUSHELD (tixagevimab and cilgavimab for injection) was authorized by Health Canada on April 14, 2022. In order to provide rapid access to EVUSHELD in the context of the global COVID-19 pandemic, AstraZeneca will distribute product vials and cartons with…
AlertHealth professional risk communication | 2022-04-14
Health alert or recall Distribution of NUVAXOVID with English-only Vial and Carton Labels
NUVAXOVID was authorized by Health Canada on February 17, 2022. In order to provide earlier access to NUVAXOVID in the context of the global pandemic, Novavax, Inc. will distribute product vials, cartons and package inserts that are in English only for a…
AlertHealth professional risk communication | 2022-02-23
Health alert or recall PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
UPDATED INFORMATION - July 6, 2022 A new PAXLOVID dose pack for use in patients with moderate renal impairment (eGFR ≥30 to <60 mL/min) is now available with a distinct DIN: 02527804. Pfizer has introduced this new packaging configuration to…
AlertHealth professional risk communication | 2022-01-17
Health alert or recall Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
There is a high risk of treatment failure with the casirivimab and imdevimab combination based on analysis of neutralization activity against selected mutations of the SARS-CoV-2 Omicron variant. The Canadian Product Monograph for casirivimab and…
AlertHealth professional risk communication | 2022-01-07
Health alert or recall Ivermectin not authorized to prevent or treat COVID-19; may cause serious health problems
UPDATE (October 19, 2021): Reports to poison centres concerning ivermectin as a prevention or treatment for COVID-19 have increased over the summer months Health Canada is reminding Canadians not to use ivermectin to prevent or treat COVID-19.…
AlertPublic advisory | 2021-10-19
Health alert or recall Authorization of Sotrovimab for Injection for Use in Relation to the COVID-19 Pandemic
Authorization of Sotrovimab for Injection for Use in Relation to the COVID-19 Pandemic Starting date: September 22, 2021 Posting date: October 4, 2021 Type of communication:…
AlertHealth professional risk communication | 2021-10-04
Health alert or recall Graphene face masks
Graphene face masks Starting date: July 13, 2021 Posting date: September 28, 2021 Type of communication: Advisory Subcategory: Medical Device Source of recall: Health Canada…
AlertPublic advisory | 2021-09-28
Health alert or recall Health Canada updates Pfizer-BioNTech COVID-19 vaccine label to reflect very rare reports of Bell's Palsy
Health Canada updates Pfizer-BioNTech COVID-19 vaccine label to reflect very rare reports of Bell's Palsy Starting date: August 6, 2021 Type of communication: Advisory…
AlertPublic advisory | 2021-08-06
Health alert or recall AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome Starting date: June 29, 2021 Posting date: June 29, 2021 Type of communication: Dear Healthcare…
AlertHealth professional risk communication | 2021-06-29
Health alert or recall Health Canada issues label change on the AstraZeneca and COVISHIELD COVID-19 vaccines
Health Canada issues label change on the AstraZeneca and COVISHIELD COVID-19 vaccines Starting date: April 14, 2021 Posting date: June 29, 2021 Type of communication: Advisory…
AlertPublic advisory | 2021-06-29
Health alert or recall Importation of COVID-19 Vaccine Moderna with up to 15 Doses per Vial and English-only Vial and Carton Labels (US-Labelled Supply)
UPDATED INFORMATION – October 29, 2021 Further to the Health Canada communications below issued on June 14, 2021 (and updated on June 24, 2021, and August 3, 2021), Health Canada has authorized a 2-month shelf life extension (from 7 months to 9 months…
AlertHealth professional risk communication | 2021-06-14
Health alert or recall Importation of Janssen COVID-19 Vaccine with Two Types of English-only Vial and Carton Labels
Importation of Janssen COVID-19 Vaccine with Two Types of English-only Vial and Carton Labels Starting date: April 26, 2021 Posting date: April 26, 2021 Type of communication…
AlertHealth professional risk communication | 2021-04-26
Health alert or recall Janssen COVID-19 Vaccine and the Risk of Thrombosis with Thrombocytopenia
Janssen COVID-19 Vaccine and the Risk of Thrombosis with Thrombocytopenia Starting date: April 26, 2021 Posting date: April 26, 2021 Type of communication: Dear Healthcare…
AlertHealth professional risk communication | 2021-04-26
Report a problem or mistake on this page
What was wrong?

You will not receive a reply. Telephone numbers and e-mail addresses will be removed.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.